3. ADMA Biologics Inc. (NASDAQ:ADMA)
ADMA Biologics, Inc. (NASDAQ: ADMA) ranks third for its specialty immunoglobulin business and improving cash generation. Second-quarter 2026 revenue totaled approximately $124.4 million, up 2% year over year. The underlying product mix was more dramatic than that modest increase suggests, with ASCENIV growth offsetting weakness elsewhere in the portfolio.
During the first half, ASCENIV revenue increased 26% to $200.4 million, while BIVIGAM revenue declined 51%. Gross margin improved to approximately 70% from 54%, and operating cash flow reached $87.8 million, compared with $1.5 million a year earlier.
Those figures support an investment argument built on product mix, manufacturing efficiency, and cash conversion. Nevertheless, management explicitly acknowledged competitive dynamics and pricing pressure in the U.S. immune globulin market.
Ranking rationale
Its improving economics earn a higher position, but modest total revenue growth and increasing reliance on ASCENIV prevent a stronger ranking.
